Guerbet Secures U.S. Approval for Elucirem Contrast Agent
The U.S. Food and Drug Administration (FDA) has approved Guerbet's Elucirem contrast agent for use in MRI scans for adults and pediatric patients aged two and older. The agent contains gadopiclenol.
French pharmaceutical company Guerbet has received approval from the U.S. Food and Drug Administration (FDA) for its Elucirem contrast agent. The agent is indicated for magnetic resonance imaging (MRI) procedures.
Elucirem is approved for adults and pediatric patients aged two years and older for the detection and visualization of lesions with abnormal vascularity in the central nervous system, head and neck, thorax, abdomen, pelvis, and musculoskeletal system. It is administered intravenously.
The approval includes warnings, notably concerning the risk of Nephrogenic Systemic Fibrosis (NSF) in patients with impaired kidney function. According to Guerbet, injection site pain and headache were the most common adverse reactions observed in clinical trials.
Elucirem is part of ongoing developments in medical imaging contrast agents aimed at improving diagnostic accuracy. The company stated that Elucirem enhances lesion detection capabilities.